Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Rohan Kalyan Rej, J. Thomas, Ranjan Kumar Acharyya, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8339-8381
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
Rohan Kalyan Rej, Joyeeta Roy, Srinivasa Rao Allu
Cancers (2024) Vol. 16, Iss. 3, pp. 552-552
Open Access | Times Cited: 18
Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer
Lilan Xin, Chao Wang, Yan Cheng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8913-8931
Closed Access | Times Cited: 8
Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12559-12585
Open Access | Times Cited: 19
Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives
Si Ha, Jiacheng Zhu, Hua Xiang, et al.
Chinese Chemical Letters (2023) Vol. 35, Iss. 8, pp. 109192-109192
Closed Access | Times Cited: 16
Design, synthesis, and antitumor activity of benzimidazole derivatives as CDK4/6 inhibitors
Xiu Jun Wang, Xiao Hou, Luyao Zhang, et al.
Journal of Molecular Structure (2024) Vol. 1309, pp. 138189-138189
Closed Access | Times Cited: 6
Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function
Silvia Belluti, Carol Imbriano, Livio Casarini
Cancers (2023) Vol. 15, Iss. 18, pp. 4653-4653
Open Access | Times Cited: 13
Mitochondrial-Targeting Nanotrapper Captured Copper Ions to Alleviate Tumor Hypoxia for Amplified Photoimmunotherapy in Breast Cancer
Wenxin Huang, Mian Yu, Shengjie Sun, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 2, pp. 2166-2179
Closed Access | Times Cited: 5
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 494-494
Open Access | Times Cited: 5
Discovery of D-Ring-Contracted Artemisinin as a Potent Hydrophobic Tag for Targeted Protein Degradation
Luolong Qing, Qi-Ying Yu, Changqi Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Efficient Stereoselective Synthesis of Vepdegestrant (ARV‐471) via Ruthenium‐Catalyzed Asymmetric Hydrogenation
Neerasa Jayaprakash, Byeonggwan Kim, Hye Jin Chung
ChemistrySelect (2025) Vol. 10, Iss. 4
Closed Access
Research progress of flavonoids targeting estrogen receptor in the treatment of breast cancer
Jianling Long, Pengju Ye, Weixi Yuan, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118106-118106
Closed Access
Breast Cancer-the-State-of-the Art in the World and Islamic Development Banks Members Countries (IsDB-MCs)
Ahmed A. M. Elnour
(2025), pp. 169-213
Closed Access
Investigating the Multi-Mechanistic Anticancer Effects of 4-Bisarylurea Thiouracil Derivatives in Breast Cancer Cells
Mohamed Fares, Muhammad A. Alsherbiny, Islam A. Elkelesh, et al.
(2025)
Closed Access
The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma
Khushboo Bhutani, S. K. Vishwakarma, Priyanka Yadav, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2025) Vol. 250, pp. 106729-106729
Closed Access
Targeted Imaging of Estrogen Receptor‐Positive Cancer Cells Using Fluorescent Estradiol Probes
Shabnam Mansuri, Sunil Ojha, Sriram Kanvah
Advanced Optical Materials (2025)
Closed Access
A practical synthesis of YZD-7082B, a novel orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer
Yongqi He, Xin-Yu Leng, Runying Wang, et al.
Molecular Diversity (2025)
Closed Access
HSD17B7 counters bone loss in estrogen deficiency via estrogen receptor stabilization and mediates the effect of raloxifene
Young Jae Moon, Junyue Zhang, Yiping Song, et al.
Research Square (Research Square) (2025)
Closed Access
Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy
Mohammad Hajimolaali, Farid Abedin Dorkoosh, Sophia G. Antimisiaris
Journal of Liposome Research (2024) Vol. 34, Iss. 4, pp. 671-696
Closed Access | Times Cited: 3
Cholesteryl ester transfer protein knock‐down in conjunction with a cholesterol‐depleting agent decreases tamoxifen resistance in breast cancer cells
Liang Gu, Ruvesh Pascal Pillay, Ruth Aronson, et al.
IUBMB Life (2024) Vol. 76, Iss. 9, pp. 712-730
Open Access | Times Cited: 3
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9
Changwei Wang, Mi Wang, Yu Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 14125-14154
Closed Access | Times Cited: 3
Heteroaryl Group Containing Trisubstituted Alkenes: Synthesis and Anti‐tumor Activity
Jiatong Li, Ao Gu, Mengyao Li
Chemistry & Biodiversity (2024) Vol. 21, Iss. 11
Closed Access | Times Cited: 3
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)
Rohan Kalyan Rej, Biao Hu, Zhixiang Chen, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Research progress of LSD1-based dual-target agents for cancer therapy
Xiaojuan Yang
Bioorganic & Medicinal Chemistry (2024) Vol. 101, pp. 117651-117651
Closed Access | Times Cited: 2
The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364
Yucheng Tian, Kang Liu, Dongdong Wu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116275-116275
Closed Access | Times Cited: 2
New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives
Jian Min, Xin Liu, Rouming Peng, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top